Shyam Varadarajulu’s Post

Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson's disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial https://lnkd.in/eYYcukeW

Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson's disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial https://lnkd.in/eYYcukeW

Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson's disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial https://lnkd.in/eYYcukeW

I am delighted to share our publication in Nature Sci Rep, "Revealing novel biomarkers for diagnosing chronic kidney disease in pediatric patients". Our study delves into the diagnosis of pediatric chronic kidney disease (CKD), highlighting the limitations of glomerular filtration rate as a diagnostic measure, especially in early stages. Our comprehensive targeted metabolomics study, involving 67 CKD and 45 healthy pediatric patients, explored potential biomarkers such as citrulline (CIT), symmetric dimethylarginine (SDMA), S-adenosylmethionine (SAM), n-butyrylcarnitine (nC4), and others, alongside creatinine. Through liquid chromatography-triple quadrupole mass spectrometry, we identified significant differences in biomarker concentrations between healthy and CKD pediatric patients. This study marks a significant step forward in pediatric CKD diagnosis and opens new avenues for early intervention. #PediatricResearch #ChronicKidneyDisease #Biomarkers #Metabolomics #NatureSciRepJournal #ScientificDiscovery #CKD https://lnkd.in/e4tpUZVX

Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson's disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial https://lnkd.in/eYYcukeW

Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson's disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial https://lnkd.in/eYYcukeW

Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson's disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial https://lnkd.in/eYYcukeW

Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson's disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial https://lnkd.in/eYYcukeW

Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson's disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial https://lnkd.in/eYYcukeW

Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson's disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial https://lnkd.in/eP2ccr6N